Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing the safety and effectiveness of giving tucatinib and trastuzumab followed by standard CAPOX chemotherapy (the drugs capecitabine and oxaliplatin) in people with locally advanced rectal cancer that has not yet been treated and makes a protein called HER2. Tucatinib and trastuzumab both block HER2, which stimulates cancer cell growth.
Atezolizumab is a standard treatment for extensive-stage small cell lung cancer (SCLC, cancer which has spread). Researchers want to see if adding valemetostat to atezolizumab therapy is safe for people with SCLC. The people in this study have extensive-stage SCLC and have completed 4 treatment cycles of atezolizumab with chemotherapy.
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
Researchers want to find the best doses of MOMA-313 alone and with olaparib in people with cancer. The people in this study have advanced castration-resistant prostate cancer (CRPC) or pancreatic cancer. CRPC is prostate cancer that has spread and keeps growing even in the absence of hormones. Their cancers also have a genetic change called HR deficiency.
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
